ArticleBulletin of experimental biology and medicine2025
A Decrease in the Content of Giant Obscurin Isoform during the Development of Isoprenaline-Induced Myocardial Injury in Rats.
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We studied changes in the content of obscurin and the corresponding mRNA in the left ventricle of rat heart during the development of isoprenaline-induced myocardial injury. Myocardial injury was induced by subcutaneous injection of β-adrenoreceptor agonist isoprenaline hydrochloride at a dose of 150 mg/kg of body weight twice with a 24-h interval. On day 14, the animals were euthanized. An increase (by 28.7%; p ≤ 0.01) in heart weight, as well as an increase (by 17.7%; p ≤ 0.01) in the heart-to-body weight ratio in rats after isoprenaline injection were observed, indicating the development of cardiac muscle hypertrophy. Western blotting with antibodies specific to the N-sequence of rat obscurin previously produced by us revealed a 1.2-fold decrease (p ≤ 0.01) in the content of the A-isoform (880 kDa) of this protein in the left ventricle of the rat heart after isoprenaline injection. This decrease was observed against the background of elevated content (4.2-fold; p ≤ 0.01) of obscurin mRNA. The role of reduced obscurin content in the deterioration of heart function during the development of isoprenaline-induced myocardial injury is discussed.
Indexed as
Identifiers
41518578What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.